Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Galaxy Digital's (GLXY) debut on the Nasdaq, Eli Lilly (LLY) getting a lift ...

ByInvesting.com • May 22, 2025 New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect Today ...

U.S. stocks are set to wrap a winning week as tariff and trade fears ease, President Trump winds down his Middle East trip ...

The move in futures comes after a broadly positive day on Wall Street. The S&P 500 rose 0.72%, while the Nasdaq Composite climbed 1.61% for its fifth straight positive session. The Dow fell 0.64%, ...

executives and their associated persons. Please find below a statement of such trading in shares issued by Novo Nordisk.

executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. Please find below a statement of such trading in shares issued by Novo Nordisk.

Novo Nordisk (NYSE: NVO) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

Novo Nordisk (NVO) stock in focus as the company promotes FDA-approved Wegovy as a ban for makers of compounding versions ...

Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons ...

MASH prevalence in Canada is projected to rise from 5.2% to 6.5% by 2030. Health Canada review could lead to the first approved treatment for MASH. Memorial Day Special: Access your full investing ...

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.